Please login to the form below

Not currently logged in
Email:
Password:

St Ives buys Hive

Says healthcare consultancy complements the company’s existing offering
st ives group logo

The marketing and publishing firm St Ives Group has bought The Hive Group as part of its strategy to create a complementary range of marketing and communications services.

Post-acquisition, the central London-based Hive Group will operate as a subsidiary of St Ives. It will continue to be run by its existing management team, including founding directors Ian Busby, Jas Hummel and Tim Scorer.  There will be no change to staff numbers, St Ives told PMLiVE.

Set up in 2008, The Hive Group today has more than 75 employees. It provides strategic consulting and communications services to an international client base, including six of the top 10 pharmaceutical companies.

The group operates across three main divisions: Hive, its strategic healthcare consultancy and communications business, Pollen, a strategic medical communications consultancy, and eBee, a specialist digital healthcare agency.

The St Ives Group chairman, Patrick Martell, said that he was delighted to welcome the Hive team to the group, adding that Hive's blend of consultancy services and digital services would complement St Ives' existing marketing services businesses.

Hive's Busby, Hummel and Scorer described the acquisition as 'a testament to the talent of our whole team and the uniqueness of our business'.

The acquisition followed a six month long global process which saw The Hive Group look at a number of potential buyers, from private equity to big global partner, to find one that was right for the brand and the business, both now and in the future.

Article by
Tara Craig

9th May 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics